Vertigo

Composition: betahistine dihydrochloride 16mg and 24mg

Pharmacotherapeutic group: antivertigo preparations.

Indications: 

• Symptomatic treatment of Meniere’s disease
• Symptomatic treatment of vestibular vertigo

Administration and dosage:

The dosage is selected individually.

Adults

16 mg tablets - ½-1 tablet, 3 times daily

24 mg tablets – 1 tablet, 2 times daily

Contraindications: hypersensitivity to betahistine hydrochloride or to any of the excipients, pheochromocytoma.

Packing: 10 tablets of 16mg or 24mg in a blister, 3 blisters in a cardboard box along with a leaflet.

Storage: store at a temperature not exceeding 25°C, out of the reach of children.

Produced by:  "Medochemie", Cyprus

See also: http://www.medochemie.com/